Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Ovarian cancer CDx gains CE-IVD certification
April 2016
EDIT CONNECT

SHARING OPTIONS:

NIEL, Belgium—Multiplicom N.V. has announced that its BRCA Tumor MASTR Plus Dx has received CE-IVD certification, making it Europe’s first CE-IVD companion diagnostic for identifying ovarian cancer patients with BRCA1 and/or BRCA2 mutations—based on the analysis of formalin-fixed paraffin-embedded (FFPE) tumor tissue—who may be candidates for treatment with PARP inhibitors. Ovarian cancer is the fifth most lethal cancer in Europe, with high-grade serous ovarian cancer, the most common type in this subset, associated with BRCA1 or BRCA2 mutations in 30 percent of patients.
 
“Treatment options are limited, but the combination of a targeted therapy with a companion diagnostic provides clinicians and patients with new options. There is a crucial need to know who is likely to respond favorably to a treatment before starting it,” said Dirk Pollet, CEO of Multiplicom. “Our BRCA Tumor MASTR Plus Dx allows local laboratories to identify patients who will benefit from a specific treatment.”\
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.